Compare PPG Industries, Inc. (PPG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs BIO-TECHNE Corp — how do they compare? PPG Industries, Inc. trades at $105.43 (market cap $23.44B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: PPG Industries, Inc. is far larger — about 2.1× BIO-TECHNE Corp's market cap, and PPG Industries, Inc. pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and BIO-TECHNE Corp for 63 Days on average.
| PPG | TECH | |
|---|---|---|
Market Cap | $23.44B | $11.36B |
Volume | 2,064,777 | 5,390,331 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $72.61 |
52-Week Low | $94.34 | $43.31 |
Typical Hold Time | 68 Days | 63 Days |
Enterprise Value | $29.31B | $11.39B |
Dividend Yield | 2.81% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $105.08, down 1.37% on the day, with technical indicators showing bearish momentum. The stock demonstrates solid fundamentals with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates, while the company maintains its Dividend King status with consistent payouts.
The outlook remains cautiously optimistic with a $130 consensus price target representing 24% upside potential. Key risks include margin pressures in the Automotive Refinish segment and European demand weakness. Analyst consensus leans bullish with 55% buy ratings, though technical weakness suggests potential near-term consolidation before fundamental strength drives recovery.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
